Summit Therapeutics (SMMT) Leases: 2019-2025
Historic Leases for Summit Therapeutics (SMMT) over the last 6 years, with Sep 2025 value amounting to $5.4 million.
- Summit Therapeutics' Leases fell 32.05% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year decrease of 32.05%. This contributed to the annual value of $7.1 million for FY2024, which is 21.93% up from last year.
- Per Summit Therapeutics' latest filing, its Leases stood at $5.4 million for Q3 2025, which was down 2.38% from $5.6 million recorded in Q2 2025.
- Summit Therapeutics' Leases' 5-year high stood at $9.4 million during Q1 2024, with a 5-year trough of $1.5 million in Q1 2021.
- Over the past 3 years, Summit Therapeutics' median Leases value was $6.4 million (recorded in 2023), while the average stood at $6.7 million.
- As far as peak fluctuations go, Summit Therapeutics' Leases skyrocketed by 403.61% in 2021, and later tumbled by 36.30% in 2025.
- Over the past 5 years, Summit Therapeutics' Leases (Quarterly) stood at $2.8 million in 2021, then soared by 49.64% to $4.2 million in 2022, then spiked by 40.34% to $5.9 million in 2023, then grew by 21.93% to $7.1 million in 2024, then slumped by 32.05% to $5.4 million in 2025.
- Its Leases stands at $5.4 million for Q3 2025, versus $5.6 million for Q2 2025 and $6.4 million for Q1 2025.